Loading
Led PACIFIC, which made a year of durvalumab after chemoradiation the standard for stage III lung cancer.
Scott Antonia was principal investigator of PACIFIC, the trial showing consolidation durvalumab after chemoradiotherapy improves progression-free and overall survival in unresectable stage III NSCLC, the first curative-intent immunotherapy result in lung cancer. He also led early nivolumab work in small-cell lung cancer (CheckMate 032). He now directs immunotherapy and cell therapy programmes at Duke.
The current standard for unresectable stage III lung cancer, and the clearest evidence in the disease that consolidation immunotherapy converts responses into cures for some patients rather than merely delaying relapse.
Patients with stage III lung cancer that cannot be removed surgically should receive a year of durvalumab after completing chemoradiotherapy, provided they have not progressed. This roughly doubles the chance of being alive without progression at five years. Whether the benefit extends to PD-L1-negative tumours is contested, and the EGFR-mutated subgroup is better served by osimertinib (LAURA).
Shares Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tags lung, immunotherapy.
Shares Nivolumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tags lung, immunotherapy.
Shares Non-small-cell lung cancer and the tags lung, immunotherapy.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag lung.
Shares Non-small-cell lung cancer and the tags lung, immunotherapy.
Shares PACIFIC, Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer.